LTRN
NASDAQLantern Pharma Inc.
News · 26 weeks42+133%
2026-03-012026-08-23
Mix1490d
- SEC Filings6(43%)
- Other6(43%)
- Earnings1(7%)
- Offering1(7%)
Latest news
25 items- SECLantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form 10-Q filed by Lantern Pharma Inc.10-Q - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business UpdateOpen Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EMA Clears LP-184, zirdafulven, for Biomarker-Selected Bladder Cancer Trial; LP-184 Development Positioned to Advance in Multiple Indications including Triple Negative Breast Cancer and Pediatric Brain Cancers Open Medicine AI (OMAI) established as a separate company with board-approved commercial licensing agreements executed, operating the multi-agentic AI co-scientist platform previously launched as withZeta.ai. OMAI is currently wholly owned by Lantern and intends to raise capital at the OMAI level. A dedicated
- PRLantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ETWebcast to be held Friday, August 14th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® and Open-Medicine AI platforms with multiple clinical stage drug programs, today announced that it will host its second quarter 2026 operating and financial results webcast on Friday, August 14, at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the second quarter ended June 30, 2026 and provide guidance on upcoming milestones, clinical trials
- SECSEC Form SCHEDULE 13G filed by Lantern Pharma Inc.SCHEDULE 13G - Lantern Pharma Inc. (0001763950) (Subject)
- SECLantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of MedicineThe Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai and is expanding into additional disease areas and modalities. The creation of the new entity, signed commercial licenses, and Board approvals are consistent with the agreements entered into in connection with Lantern’s May financing. Lantern Pharma has executed commercial licensing agreements with Open-Medicine AI granting access to Lantern’s withZeta.ai-related models, data, algorithms, and other assets and personnel. The global AI drug discovery and development market is projected to exceed $10 billion by 2030, and Open-Medicine AI enters this market with a differentiated
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lantern Pharma Inc.SCHEDULE 13G/A - Lantern Pharma Inc. (0001763950) (Subject)
- PRLantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor CancersAllowed patent claims cover the use of a three-gene expression signature — PTGR1, PTPN14, and ASPH — to identify patients for treatment with LP-184 (Zirdafulven) In a completed 63-patient Phase 1a trial, LP-184 demonstrated a 45% disease control rate (n = 29) among patients with recurrent or refractory advanced cancers treated at or above the effective therapeutic dose LP-184 is planned to be evaluated in multiple precision oncology Phase 1b/2 clinical trials in advanced aggressive and rare cancers during 2026 Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today anno
- PRLantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every CancerFirst previewed in the company’s May roadmap, the new withZeta.ai module now enters early access with leading bioinformatics teams and Lantern collaborators — autonomously designing experiments, building rigorous cohorts from 615,000+ curated cancer samples, and delivering publication-ready multi-omic analysis in minutes A new class of research agent. ZetaOmics™ is an autonomous "Computational Biologist" that goes beyond automating software — it reasons about experimental design, prevents pitfalls that produce false discoveries, and makes statistically rigorous decisions on its own, encoding the judgment of a tenured bioinformatician so that scientific rigor is the default across rare an
- SECSEC Form EFFECT filed by Lantern Pharma Inc.EFFECT - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form S-1 filed by Lantern Pharma Inc.S-1 - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung CancerExon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile. PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall (n=15) – future patients will be eligible to receive up to 8 doses of LP-300. Durable, deep responses: tumor reduction in over 70% of evaluable L858R patients, responses beyond two years, and a 77% clinical benefit rate. Clean, treatment-enabling safety: no clinically meaningful toxicity beyond chemotherapy, comparing favorably with amivantamab plus
- SECLantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form D filed by Lantern Pharma Inc.D - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLCThe FDA raised no objections to Lantern's key proposed protocol amendments to the HARMONIC™ clinical trial. Amendments include: (1) enriching enrollment for patients with EGFR exon 21 L858R mutations; (2) extending LP-300 dosing to a maximum of eight cycles; and (3) transitioning to a single-arm study design — changes that align with emerging data and support a clearer regulatory and partnering path. EGFR exon 21 L858R mutations account for approximately 40% of all EGFR-mutant NSCLC globally and up to 50% in Asian populations — a molecularly defined subset that consistently experiences inferior outcomes when treated with current EGFR-targeted therapies relative to patients with exon
- SECLantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- SECSEC Form 10-Q filed by Lantern Pharma Inc.10-Q - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business UpdatesDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million Q1 net loss reduced 27% year-over-year while progressing multiple precision oncology programs Commercial introduction of withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex cancer drug development Successful outcome from Type C meeting request with the FDA focused on the LP-300 HARMONIC™ Clinical Trial Pediatric brain cancer IND cleared by FDA for enrollment for Lantern Pharma subsidiary, Starlight Therape
- SECLantern Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Lantern Pharma Inc. (0001763950) (Filer)
- INSIDERDirector Keyser D Jeffrey bought $100,001 worth of shares (48,544 units at $2.06), increasing direct ownership by 106% to 94,303 units (SEC Form 4)4 - Lantern Pharma Inc. (0001763950) (Issuer)
- INSIDERDirector Schalop Lee Troy bought $100,001 worth of shares (48,544 units at $2.06) (SEC Form 4)4 - Lantern Pharma Inc. (0001763950) (Issuer)
- PRLantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor$4.4 million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants Offering priced at the closing price with unregistered warrants exercisable at a 10% premium to the close and non-exercisable for the first six months Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with multiple clinical stage drug programs, today announced the closing of its previously announced registered direct offering of 2,135,923 shares of its common stock (or pre
- SECSEC Form 424B5 filed by Lantern Pharma Inc.424B5 - Lantern Pharma Inc. (0001763950) (Filer)
- PRLantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor$4.4 million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants Offering priced at the closing price with unregistered warrants exercisable at a 10% premium to the close and non-exercisable for the first six months Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with multiple clinical stage drug programs, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,135,923 shares of i
LTRN FAQ
7 questionsWhat does Lantern Pharma Inc. do?
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain...Where does LTRN stock trade?
Lantern Pharma Inc. (LTRN) is listed on NASDAQ.What sector and industry is LTRN in?
Lantern Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Lantern Pharma Inc. go public?
Lantern Pharma Inc. (LTRN) completed its IPO in 2020.What are analysts saying about LTRN?
Lantern Pharma Inc. has had 3 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $3600.00 price target on 2022-03-11. Recent price targets range from $3200.00 to $3600.00.What companies are similar to LTRN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LTRN side-by-side with any of them on Quantisnow.How can I track LTRN on Quantisnow?
Quantisnow aggregates Lantern Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LTRN to receive live email and push alerts on every new disclosure.